NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

NGM Biopharmaceuticals, Inc. announced it has dosed the first patient in a Phase I/Ib clinical trial of NGM831, an antagonist antibody product candidate designed to block the interaction of ILT3 with fibronectin, a key component of the tumor stroma, for the treatment of patients with advanced solid tumors.